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Background: Lethal toxin (LT) is a major virulence factor of Bacillus anthracis. Sprague Dawley rats manifest
pronounced lung edema and shock after LT treatments, resulting in high mortality. The heart failure that is induced
by LT has been suggested to be a principal mechanism of lung edema and mortality in rodents. Since LT-induced
death occurs more rapidly in rats than in mice, suggesting that other mechanisms in addition to the heart
dysfunction may be contributed to the fast progression of LT-induced pathogenesis in rats. Coagulopathy may
contribute to circulatory failure and lung injury. However, the effect of LT on coagulation-induced lung dysfunction
is unclear.
Methods: To investigate the involvement of coagulopathy in LT-mediated pathogenesis, the mortality, lung
histology and coagulant levels of LT-treated rats were examined. The effects of activated protein C (aPC) on
LT-mediated pathogenesis were also evaluated.
Results: Fibrin depositions were detected in the lungs of LT-treated rats, indicating that coagulation was activated.
Increased levels of plasma D-dimer and thrombomodulin, and the ameliorative effect of aPC further suggested that
the activation of coagulation-fibrinolysis pathways plays a role in LT-mediated pathogenesis in rats. Reduced
mortality was associated with decreased plasma levels of D-dimer and thrombomodulin following aPC treatments
in rats with LT-mediated pathogenesis.
Conclusions: These findings suggest that the activation of coagulation in lung tissue contributes to mortality in
LT-mediated pathogenesis in rats. In addition, anticoagulant aPC may help to develop a feasible therapeutic
strategy.
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Anthrax is a disease caused by infection with the Gram-
positive bacterium Bacillus anthracis. Anthrax is charac-
terized by massive bacteremia in the absence of an
effective immune response. Lethal toxin (LT) is a
major virulence factor for B. anthracis that plays vital
role in pathogenesis and the suppression of the host
immune response [1,2]. LT is a binary protein complex
that is composed of protective antigen (PA), a host-cell
receptor binding subunit that mediates the cellular
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reproduction in any medium, provided the orwhich is a metalloprotease that inactivates the
mitogen-activated protein kinase kinases (MEKs) sig-
naling pathways [2]. Although LT treatments might
not reflect all features of B. anthracis infections, re-
ductionistic approaches investigating the effects of LT
in vitro and in vivo have aided in the elucidation the
underlying pathogenic mechanisms in anthrax [3,4]. LT
treatments in rodents resulted in hemorrhage, shock,
and hypoxic tissue damages with high mortality [5-10].
In contrast to sepsis, treatments of LT do not induce
strong proinflammatory cytokine and nitric oxide
releases in rodents [4,8,11]. LT-treated rats displayed
acute lung edema and accelerated progression of patho-
genesis, compared with mice [4]. Recent findings suggest
that LT can suppress cardiac function [3,12-14]. Because. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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body fluid in the lungs [15,16], the lung edema asso-
ciated with LT treatments in rodents may be a secondary
manifestation of the failing heart [3,4,7,14]. Since LT-
induced death is much faster in rats than in mice, this
suggests that other mechanisms in addition to the heart
dysfunction may be contributed to the fast progression
of LT-induced pathogenesis in rats. Coagulopathy causes
hemodynamic changes [17,18], and the conversion of
extravascular fibrinogen into fibrin in the airway lumen
can exacerbate lung injury [19,20]. LT–induced coagulo-
pathy has been observed in mice [5,6]. However, the
role of coagulopathy in LT-treated rats remains largely
unclear.
Featured by abnormal activation of coagulation system,
coagulopathy is frequently observed in a severe patho-
logical condition like sepsis, which manifests with pro-
longed plasma clotting time and decreased circulating
anticoagulant protein C [21,22]. Protein C is an inactive
zymogen of a soluble, vitamin K–dependent, plasma
serine protease that plays a central role in endogenous
anticoagulation [23]. The activation of protein C requires
binding to the endothelial protein C receptor and the
thrombomodulin-thrombin complexes on the endothe-
lium [23]. Decreased circulating protein C and increased
circulating thrombomodulin are indicators of dysfunc-
tional anticoagulation that lead to the prothrombotic,
hypercoagulable states which are associated with sepsis
and acute lung injury [21,24-28]. B. anthracis infections in
humans and animals may lead to coagulopathy with ele-
vated levels of plasma D-dimer [29-31]. Released into the
circulation during the degradation of fibrin during fibrin-
olysis, D-dimer is widely used as a marker for the detec-
tion of coagulopathy [32]. Anthrax LT is a virulence factor
of B. anthracis. However, such coagulant pathological
changes were primarily observed in B. anthracis infections
but not clearly demonstrated in LT-treated rats.
We investigated the role of coagulopathy in LT-
induced pathogenesis in rats. Analyses of tissue sec-
tions, plasma clotting time, key coagulant factors, and
hemodynamic parameters were performed to evaluate
the coagulant status of LT-treated rats. Our analysis of
plasma D-dimer and thrombomodulin levels suggest
that coagulopathy is involved in LT-induced pathoge-
nesis, and our observations of the ameliorative effects
of activated protein C (aPC) on LT-induced coagulopa-
thy support our findings. The regulation of coagulation
and the pathological responses in rats are compared
with those of mouse models.
Methods
Animals
Male Sprague Dawley rats aged 8 to 10 weeks that were
free from specific pathogens, were purchased from theNational Laboratory Animal Center, Taiwan. Rats were
intravenously treated with either 0.25 mg/kg of PA or
0.25 mg/kg of LT (LF : PA = 15 : 85; a lethal dose), re-
spectively. Rats will die from LT-induced pathogenesis at
4 to 7 hours following the LT injections. Lipopolysac-
charide (LPS, Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in phosphate-buffered saline (PBS, pH 7.4) and
used as a control to induce coagulopathy. The LPS treat-
ments (20 mg/kg) were performed over the same time
course as PA and LF injections. XigrisW (drotrecogin
alfa, Eli Lilly & Co., Giessen, Germany), a recombinant
form of human aPC, was administrated intravenously
every 4 hour (96 μg/kg/injection) for the total of three
injections as a modification of the manufacturer’s
instructions. Because the Xigris was diluted in normal
saline, the control rats were injected with an equivalent
amount of saline for comparison. The experiments were
performed in accordance with institutional guidelines.
All animal research methods were approved by the Ani-
mal Care and Use Committee of Tzu Chi University (ap-
proval ID: 97005).
Toxin preparation and usage
Components of Bacillus anthracis lethal toxins, LF and
PA, were prepared and purified as previously described
[33-35]. Doses of LT contained LF and PA at a ratio of
15:85, respectively, such that 100 μg LT contained 15 μg
LF plus 85 μg PA, which is roughly equivalent to the
composition of native toxin. Purified proteins were ana-
lyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE). Using Image J software
(National Institutes of Health, Bethesda, MD, USA), 85-
90% purity was estimated for the total protein fractions.
LPS was monitored using a Limulus Amoebocyte Lysate
QCL-1000 kit (Lonza, Walkersville, MD, USA), and the
level of LPS contamination was less than 1 EU/mg LT, a
level of LPS that we observed to be incapable of eliciting
significant inflammatory cytokine IL-1 and TNF-α secre-
tion in vitro and in vivo (data not shown).
Analysis of plasma proteins in plasma and lung tissue
fluid
We measured the relative levels of albumin, immuno-
globulin G (IgG) and fibrinogen in the plasma/lung
homogenate fluid of surviving rats at four hours fol-
lowing the LT treatments (0.25 mg/kg) using enzyme-
linked immunosorbent assay (ELISA). This time point
demonstrated 30% mortality and therefore was
expected to reveal pathophysiological changes of the
lethal pathogenesis. The lung tissue of rats (0.5 g) was
homogenized in 1 mL extraction buffer (10 mM Tris,
150 mM NaCl, pH 7.4) at 4°C using a tissue
homogenizer (PRO Scientific, Oxford, CT, USA). The
homogenates were transferred to 1.5 mL Eppendorf
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4°C. The supernatant (lung-tissue fluid) was stored at
−80°C until analyzed. The total protein in the plasma
and lung-tissue fluid was determined by the method of
Bradford. Plasma or lung tissue fluid (50 μg/well) was
coated on 96-well dishes with at 37°C for 2 hours.
After blocking with 5% BSA for additional 1 hour and
3 washes, the wells were then separately probed using
anti-albumin (Abcam, Cambridge, MA, USA), anti-rat
IgG (Jackson Immunoresearch Laboratory, West
Grove, PA, USA) and anti-fibrinogen (Abcam) anti-
bodies. Plasma of phosphate-buffered saline (PBS, pH
7.4)-treated rats served as a vehicle control. Plasma
samples were used neat or diluted four-fold with PBS
to keep the ELISA signal in a linear range. The plasma
protein levels of treated rats were normalized to those
of the vehicle controls.
Histology and immunohistochemistry
Lungs of animals treated with LT (0.25 mg/kg) for 4
hours were fixed with 10% buffered formalin (Sigma-
Aldrich) and embedded in paraffin. Tissue sections were
then deparaffinized and stained with hematoxylin and
eosin (H&E), and immunoglobulin (Ig). Tissue section
images were obtained using a Leica DMIRE2 microscope
(Wetzlar, Germany). Staining of fibrin was performed as
previously described [36] using deparaffinization; 3%
H2O2, 10 minutes; Tris-buffered saline (TBS) with 0.05%
Tween (TBST); 0.1% proteinase K in TBS, 10 minutes;
TBST; 1:1000 chicken anti-human fibrinogen (Abcam,
Cambridge, MA), which cross reacts with rat fibrinogen
and fibrin (data not shown), in an overnight incubation
at 4°C. Bound primary antibody was visualized using an
anti-chicken antibody-peroxidase conjugate and the DAB
(3,3’-diaminobenzidine tetrahydrochloride) substrate,
and sections were counterstained with hematoxylin.
Purified total IgGs from non-immunized rabbits were
used for the control staining.
Hemoglobin analyses of lung fluid
Whole blood samples were collected from the tail veins
of surviving rats at 4 hours following LT treatment and
mixed 9:1 with ACD anticoagulant solution (38 mM cit-
ric acid, 75mM sodium citrate, 100mM dextrose)
[37,38]. These blood samples were used as controls for
comparisons to lung tissue and interstitial fluid. The
hemoglobin levels were determined using a Drabkin’s re-
agent (Sigma-Aldrich) (ACD and blood : Drabkin’s re-
agent = 1:500) according to previously described
methods [39,40]. Serially dilutions were used to plot a
standard curve. Hemoglobin levels in the samples from
LT-treated rats were normalized to the levels in the
whole blood of vehicle controls. The 1:4 dilutions of
control blood were used as reference points to maintaina linear data range within the detection limits of the
method.Blood oxygen measurement
At 4 hours following the LT treatments, surviving rats
were anaesthetized by intraperitoneal injection of pento-
barbital (30 mg/kg). Cardiac puncture of the (right ven-
tricle) was used to collect blood in 50 IU/ml lithium
heparinized syringes, and the blood oxygen content
(PO2) was measured directly by the method of ampero-
metry in a blood gas analysis machine (Synthesis series,
Instrumentation Laboratory, Lexington, MA, USA).Cell death analysis
The mouse macrophage-like cell line J774A.1 (ATCC
TIB67) was used for cytotoxicity analysis [34,35,41]. The
cells were maintained in Dulbeco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum
(FBS). The cells (1 × 105/well) were treated with a cyto-
toxic dose of LT (15 ng/mL), with or without additional
treatments of aPC (Xigris; 1.5 μg/mL), in 96-well dishes
for 3 hours. The level of viable cells was determined
using the WST-1 kit (Roche Diagnostics, Indianapolis,
IN, USA) according to the manufacturer’s instructions.Coagulant analyses
Plasma levels of D-dimer, thrombomodulin, protein C
and antithrombin III levels in mice were determined be-
fore (0 hour), and after (2 and 4 hours) PA, LT and LPS
treatments using a D-dimer ELISA kit (American Diag-
nostica, Stamford, CT, USA), a thrombomodulin ELISA
kit (Abcam) and chromogenic protein C and antithrom-
bin III kits (American Diagnostica), respectively [36].
Activated partial thromboplastin time (aPTT) and pro-
thrombin time (PT) analyses were performed to distin-
guish between the effects of LT on the intrinsic and
extrinsic coagulation pathways, using an ACL Futura
Plus coagulometer (Instrumentation Laboratory) as
described [5].Statistical analysis
Means and standard deviations for quantifiable data
were calculated using Microsoft Office Excel 2003 for
Windows. Comparisons between groups of nonpara-
metric data were made using an ANOVA. For survival
studies, the log-rank test was performed to determine
significance using the Online Application Survival Ana-
lysis Lifespan Assays (http://sbi.postech.ac.kr/oasis) [42].
The unpaired Student’s t test was used to analyze the
parametric data for other results. Results with p values
less than 0.05 were considered statistically significant.
Figure 1 Analyses of lung fluid and coagulant abnormalities.
Sprague Dawley rats were treated with 0.25 mg/kg protective
antigen (PA) or 0.25 mg/kg lethal toxin (LT) for 4 h to induce
pathogenesis. The experimental outline is illustrated in panel A.
(B) Relative levels of albumin (Alb), immunoglobulin (IgG), and
fibrinogen (Fib) in rat plasma and lung homogenate tissue fluid
were determined. Protein levels in plasma of the vehicle control
group were adjusted to 100% in the respective groups (Alb: 3.24 ±
0.26 g/dL, IgG: 797 ± 86 mg/dL, Fib: 119 ± 8 mg/dL; B, vehicle
groups, n = 5; ** p < 0.01 compared to lung tissue fluid of both
vehicle and PA groups). (C) Relative plasma D-dimer levels were also
determined (n = 5; * p < 0.05, LT-4hr vs. PA-4 h groups). (B-C) Data
were obtained from two experiments with 2 and 3 replicates,
respectively.
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Pulmonary abnormalities
Sprague Dawley rats were intravenously treated with a
lethal dose of LT (0.25 mg/kg, LF : PA = 15 : 85, a ratio
approximately equivalent to Bacillus anthracis derived-
LT; 100% mortality) to investigate LT-induced pathoge-
nesis. Mortality occurred approximately 4 to 7 hours
after the treatment. One of the most prominent patho-
logical signs in LT-treated rats is the lung edema [7,43].
To verify whether extravascular plasma or secreted-fluid
from lung cells had contributed to the lung edema, the
levels of albumin, IgG and fibrinogen in the lung ho-
mogenate fluid were examined. The ELISA data revealed
that these plasma proteins were all detectable in the lung
tissue fluid following LT-treatments. The levels of the
plasma proteins in the lung fluid were approximately
equivalent to those in the plasma of vehicle controls,
and were significantly higher than those of lung tissue
fluid of both the vehicle controls and the PA-
treatments (Figure 1A, experiment outline, 1B, ** p <
0.01, vs. lung tissue fluid of vehicle and PA groups).
These results suggest that the lungs of LT-treated rats
experienced massive extravascular plasma leakage. D-
dimer is a fibrinogen protein fragment produced upon
a coagulation-fibrinolytic activation. D-dimer was signifi-
cantly elevated in the plasma following LT treatments
(Figure 1C), compared with PA control rats (p < 0.05),
which indicates that the coagulation-fibrinolytic cascade
was initiated. H&E staining (Figure 2A) and immuno-
histochemistry (Figure 2B) using anti-fibrinogen/fibrin
antibodies were performed to examine the coagulant ac-
tivation within the alveoli, and severe lung edema was
observed, which is consistent with previous reports
[7,43]. The H&E staining pattern of lung tissue sections
of PA-treated rats was similar to the vehicle control
groups (data not shown). Thus, PA did not induce
pathological responses in rats. Compared to the PA
groups (Figure 2A-1,3), the alveoli of LT-treated rats
contained significantly more fluid (Figure 2A-2,4).
Immunohistochemistry data also showed that extravas-
cular fibrinogen and fibrin were distributed throughout
the fluid-containing alveoli of LT-treated rats, but were
rare in PA-treated controls (Figure 2, fibrinogen/fibrin:
brown-color stained regions, estimate to occupy ap-
proximately 50% of alveoli of LT groups; PA: 2B-1,3, vs.
LT: 2B-2,4). The strong immunostaining of fibrinogen/fi-
brin was observed in the lung tissue of LT-treated ani-
mals (Figure 2B-4, asterisk marked brown-color fibrous
substances). These results suggested that coagulant cas-
cades were initiated in the lungs of LT-treated rats.
To determine whether the LT-induced lung edema
was caused by increased vascular permeability or by
hemorrhage, the hemoglobin content of lung tissue fluid
was compared with that of plasma and whole-bloodsamples. Only background levels of hemoglobin were
detected in the lung tissue fluid of LT-treated rats
(Figure 3, LT lung tissue fluid vs. vehicle, PA and LT
plasma groups). Despite previous reports that LT
induced hemolysis in vitro [44], LT treatment did not
cause significant hemolysis of erythrocytes in our
Figure 2 Lung tissue sections of rats. Protective antigen (PA) and lethal toxin (LT) (0.25 mg/kg) were injected into Sprague Dawley rats for four
hours to induce pathogenic responses. Lung tissue sections from the PA- (A-1,3, B-1,3) and the LT- (A-2,4, B-2,4) treated rats were stained with
hematoxylin and eosin (A) and anti-fibrinogen/fibrin antibodies (B). The asterisks * refer to the brown-colored regions that indicate the
localization of the anti-fibrinogen/fibrin antibodies (B-4).
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treated rats (Figure 3). Thus, the LT-induced lung edema
was likely caused by extravascular plasma (Figure 1B), ra-
ther than hemorrhaging (Figure 3, no induction of
hemoglobin in LT lung tissue fluid groups). Although,
systemic coagulopathy is frequently accompanied by
thrombocytopenia [22], no systemic changes in platelet
counts have been observed in LT-treated rats [11]. Con-
sistent with the results of previous studies [11,45], theFigure 3 Hemoglobin analysis. Hemoglobin levels in lung tissue
homogenate fluid, plasma, and whole blood from PA- and
LT-treated rats were determined. The hemoglobin level of whole
blood from the vehicle group was set at 100% for the normalization
of the data. The vehicle (1/4 diluted) data indicate the reference
point of whole blood samples of vehicle-treated group that were
diluted to 25% by the addition of phosphate buffered saline. Data
were obtained from 3 experiments with 2 replicates (34n = 6).
** p < 0.001, compared to the vehicle lung tissue fluid group.complete blood count data showed that the PA and LT
treatments did not significantly reduced the levels of pla-
telets, erythrocytes, or leukocytes in LT-treated rats (data
not shown). In addition, our examination of the brain,
heart, lung, liver, kidney, spleen, and intestine of LT-
treated rats showed that only the lung tissues exhibited
significant extravascular fibrin staining, compared with
PA-treated rats (Figure 2, lung; other data not shown).
Thus our D-dimer and immunohistochemistry data
(Figure 1 and 2) suggest that the activation of the
coagulation-fibrinolysis cascades was restricted to the
lung.
Ameliorative effect of activated protein C in LT-mediated
pathogenesis
Fibrin inactivate surfactants, and coagulation activation
in the lung has been shown to exacerbate allergic air-
way inflammation [20]. In contrast, anticoagulants have
been shown to have an ameliorative effect on lung in-
flammation [19,46]. Therefore, we evaluated the effect
of recombinant aPC on LT-induced pathogenesis in
rats. The data revealed that aPC treatments signifi-
cantly reduced LT-mediated mortality, compared with
PA-treated controls (Figure 4A, experiment outline; 4B,
LT 0% survival, vs. LT + aPC 33% survival; LT vs. LT +
aPC, ** p < 0.005). In addition, aPC-mediated ameliora-
tion on blood oxygen levels were also correlated to the
mouse survival (Figure 4C, amelioration in LT + aPC
treated survivors, but not nonsurvivors; * p < 0.05,
vs. LT groups). To determine whether the protective
effect of aPC was the result of the direct inactivation
of LT through protease activity of aPC, cytotoxicity
Figure 4 Activated protein C (aPC) treatments reduce lethal
toxin (LT)-mediated mortality. (A) The experimental outline is
illustrated. (B) The comparison of the mortality of LT-treated rats with
or without aPC at 0 to 12 h following protective antigen (PA)- or
LT-treatments (LT, 0.25 mg/kg single dose; aPC, 96 μg/kg/4 h; n = 15)
was plotted as Kaplan-Meier curves (LT vs. LT + aPC, ** p < 0.005).
The survivors in the LT + aPC group were observed for 2 mo. (C) The
blood oxygen content of rats after LT (0.25 mg/kg) and LT plus aPC
(LT + aPC) treatments for 4 h. Vehicle and LT data were collected
from 3 experiments with 2 replicates (n = 6). The data for LT + aPC
survivors and nonsurvivors were collected from 2 experiments with
2 replicates (n = 4; * p < 0.05 compared to the LT group). The
nonsurvivors were those rats that survived the first 4 h of treatment,
but died later (4 to 7 h). The survivors were those rats that survived
the entire course of treatment (B and C; LT + aPC groups).
Kau et al. Journal of Biomedical Science 2012, 19:98 Page 6 of 10
http://www.jbiomedsci.com/content/19/1/98experiments were performed using mouse macrophage
J774A.1 cells, as described [34,35]. The results of the
cytotoxicity experiments showed that aPC treatments
did not significantly rescue the J774A.1 cells from theeffects of the LT-mediated cytotoxicity (data not
shown), indicating that aPC does not inactive LT
through a direct inactivation.
Induction of plasma D-dimer and thrombomodulin
are associated with coagulopathy and lung injury
[27,32,36]. To investigate whether the ameliorative effect
of aPC is associated with the suppression of coagulopa-
thy, the plasma levels of D-dimer and thrombomodulin
were compared to other coagulant parameters including
aPTT, PT, protein C and antithrombin III. Because aPC
has an ameliorative effect on LPS-induced coagulopathy
[21,22], the amelioration of LT-induced coagulopathy was
compare to that caused by LPS-treatments (20 mg/kg),
and the results showed that aPC treatments significantly
suppressed both the LT- and the LPS-mediated induction
of plasma D-dimer and thrombomodulin (Figure 5A, ex-
periment outline; 5B, D-dimer; 5C, thrombomodulin).
However, the data from those survivors may tend to
show a relatively weaker effect (Figure 5, 1-h groups)
because mortality was first observed at 4-h following LT
treatment (Figure 4B). Therefore, the extent of the
changes in LT-induced coagulopathy may not be fully
demonstrated in our results (Figure 5). Systemic con-
sumptive coagulopathy in sepsis may exhaust both coagu-
lant and anticoagulant factors, which may be manifested
as prolonged plasma clotting time [21]. The results of ana-
lyses of aPTT and PT showed that LT treatments did not
significantly change the clotting time at 2 or 4 h following
LT treatment, compared with vehicle controls (Additional
file 1: Figure S1A and S1B). This is distinct from the
effects of LPS treatment, which significantly increased
clotting time (Additional file 1: Figure S1A and S1B, LPS
vs. vehicle groups, † p < 0.05). Similarly, plasma levels of
protein C and antithrombin III were significantly reduced
by LPS treatment (p < 0.05), but were not reduced by LT
treatments (Additional file 1: Figure S1C and S1D), and
treatment with aPC ameliorated the LPS-induced reduc-
tion of protein C and antithrombin III (Additional file 1:
Figure S1A and S1D, LPS vs. LPS + aPC groups, * p <
0.05, ** p < 0.01). These results suggest that systemic coa-
gulopathy is not involved in LT-mediated pathogenesis in
rats.
Discussion
Pulmonary edema and lesions are frequently observed
in inhalation anthrax [29,47,48]. Elevated plasma D-
dimer indicates coagulopathy in anthrax patients
[29,30]. These manifestations are reflected in the results
of in the rat experiments described in this study. Com-
pared to the rat model, several pathological features of
coagulant regulation are distinct in mice. LT induces
thrombocytopenia in mice [5,8], but not in rats [11].
The results of our D-dimer analyses suggest that coagu-
lopathy is involved in LT-mediated pathogenesis in rats
Figure 5 Analysis of the effects of activated protein C (aPC) in rats treated with protective antigen (PA), lethal toxin (LT), or
lipopolysaccharide (LPS). The experimental outline is illustrated in panel A. The plasma D-dimer (B) and thrombomodulin (C) levels of PA-, LT-,
or LPS-treated rats with and without aPC treatment at 0, 2, and 4 h following the PA, LT, or LPS treatments. The LPS treatments served as positive
controls for the induction of coagulopathy (B-C, LPS groups: induction of D-dimer, thrombomodulin in B, C). In panels B and C, the levels for the
vehicle group were set at 100 % for the normalization of the data. For the comparisons that are indicated in B and C, * p < 0.05, ** p < 0.01, and
*** p < 0.001. For the comparisons to the vehicle group, † p < 0.05, †† p < 0.01, ††† p < 0.001. Data were collect from 3 experiments with 2
replicates (n = 6).
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[29,30], but not in mice [5]. The protective role of aPC
in LT-mediated mortality in rats (Figure 4B), further
suggests a role of coagulopathy. In contrast, the lack
aPC-mediated amelioration of LT-induced pathogenesis
in the C57Bl/6J mice in our lethal dose experiments
indicates that coagulopathy does not contribute signifi-
cantly to mortality in mice (data not shown). Despite
these distinct differences in coagulopathy, LT-induced
cardiopathy is similar in the rat and mouse models
[3,4,7,12-14]. The significant differences in lung pa-
thology indicate a mechanism other than heart dysfunc-
tion. Thus, coagulopathy was a consideration. Although
no obvious systemic changes in clotting time or plasma
anticoagulants were observed, fibrin deposition was
observed in the lung sections, suggesting that the lung
is the primarily organ affected by LT-induced coagulo-
pathy in rats.
In the absence of systemic coagulopathy, localized acti-
vation of coagulation in the lung may cause significant
pathology. LT-induced pathogenesis in rats shares com-
mon features with acute lung injury and acute respira-
tory distress syndrome in humans, including multiple
organ dysfunction, intra-alveolar coagulation with fibrin
deposition on the hyaline membrane [49,50], and
decreased mortality with aPC treatment [19]. Coagulant
activation and the presence of fibrin is known to be
associated with the pathophysiology of lung injury
[19,20,51,52], and LT has been shown to increase the
paracellular permeability of endothelial cells [53]. Our
data indicate that this increased permeability results in
the extravasation of fibrinogen and fibrin into the alveo-
lar lumen (Figure 1B, 2L).Fibrinogen, fibrin and related degradation products
have been shown to suppress surfactant functions in the
alveoli [51,52]. The activation of coagulation pathways
can induce local leukocyte traffic and endothelial cell
permeability [54] that may exacerbate lung injury [20,54].
The elevation of D-dimer following LT treatment indicates
the initiation of the coagulation-fibrinolysis cascade
(Figure 1C; Figure 5B). Unlike endothelial cells, the cells
comprising the alveolar surface do not express thrombo-
modulin. The LT-induced release of endothelial thrombo-
modulin into the plasma that supposedly will suppress
vascular anticoagulant protein C pathway. Because the
LT-induced coagulopathy is primarily restricted to the
lung, the circulating plasma level of aPC may not increase
in the same manner as occurs in LPS-treated animals
(Figure 5F, LT vs. LPS). Since aPC can inactivate the co-
agulation cascade and block fibrin formation [23], this
suggests the ameliorative role of aPC in LT-treated ani-
mals (Figure 4f, 5). The anticoagulant and anti-
inflammatory activities of aPC play protective roles in lung
injury and asthma [55]. Because LT-mediated pathogen-
esis does not induce significant secretion of proinflamma-
tory cytokines [8,11], anticoagulant activity of aPC is
likely the major effect that contributes to the amelior-
ation of LT-induced pathogenesis.
Recombinant aPC (Xigris) was previously approved by
United States Food and Drug Administration (FDA) for
the reduction of mortality in adult patients with severe
sepsis [56]. Xigris was, however, withdrawn from the
market by the manufacturer after the failure of its world
wide trail to treat severe sepsis [57,58]. LT-mediated
pathogenesis does not induce a prominent inflammatory
response [8,11], and the changes in aPTT, PT, protein C,
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endotoxin-induced sepsis (Figure 5D and 5G). Thus, LT-
induced pathogenesis is significantly different from sep-
sis. As a result, Xigris may, nonetheless, ameliorate
LT-mediated pathogenesis by re-establishing the regula-
tion of coagulation. Further investigations of the ame-
liorative effects of Xigris on LT-mediated pathogenesis
are warranted.
Consistent with the results of previous studies [12,13],
the mean blood pressure of the LT-treated rats signifi-
cantly decreased at approximately 4 h following LT
treatment (Additional file 1: Figure S2A vs. Figure S2B).
To ascertain whether the elicitation of lung edema oc-
curred prior to the circulatory collapse, we examined the
extent of lung injury by measuring the blood pressure
and the lung wet-to-dry weight ratio of LT-treated rats.
We found that both pulmonary and circulatory abnormal-
ities were induced over a similar time course (Additional
file 1: Figure S2A-B; 4-hour, LT + vehicle vs. vehicle
groups). The changes in levels of plasma D-dimer and
thrombomodulin were also associated with a similar time
course (Figure 5B-C, 4-hour groups). Thus, the LT
treatments elicited both coagulation-mediated lung in-
jury (Figure 5 and Additional file 1: Figure S2C) and
heart dysfunction (Additional file 1: Figure S2B) in rats.
Therefore, we propose a hypothetical model for LT-
mediated pathogenesis that is based on the hemo-
dynamic changes and the altered coagulation occur-
ring simultaneously (Additional file 1: Figure S3).
Severe heart failure leads to the redistribution and
accumulation of body fluid in the lung [15,16], which
would likely exacerbate the increased vascular perme-
ability and the coagulation-activation in the lungs of
LT-treated rats. Coagulopathy may also negatively in-
fluence cardiac function, resulting in further hemodynamic
changes [17,18]. Dysregulation of protein C activation and
thrombosis are also caused by secondary pulmonary
hypertension, a known effect of severe heart failure
[59]. As a result, these two pathogenic events may have
potential for mutual exacerbation (Additional file 1: Figure
S3). Thus, the interruption of this exacerbating feedback
by aPC treatment may contribute to the improved survival
rate (Additional file 1: Figure S3). The cross-talks between
these two types of pathogenic regulations are interesting
issues and worthy to be further investigated.
In addition to LT, B. anthracis releases other toxins that
perturb coagulation and vascular processes during infec-
tion. Bacteria-derived metalloproteases have been shown
to degrade von Willebrand factor and ADAMTS13, which
contribute to the recruitment of platelets to the injured
vessel wall [60]. In addition, bacterial protease InhA
has been shown to inhibit fibrinolysis by activating
plasminogen activator inhibitor-1 [61-63], and anthroly-
sin O, a cholesterol-dependent cytolysin and a Toll-likereceptor 4 agonist, has been shown to disrupt endo-
thelial and epithelial barriers [64-66]. Combined treat-
ments of anthrolysin O and edema toxin significantly
induced thrombin activity in human umbilical vein
endothelial cells [67]. These studies indicate that B.
anthracis-derived secretory factors play important roles
in anthrax consumptive coagulopathy. Further investi-
gations are needed to reveal the combined effects of
these virulence factors on circulatory homeostasis du-
ring infection.
Conclusions
In summary, our results suggest that the activation of the
coagulation-fibrinolysis cascade is involved in LT-
mediated pathogenesis in rats. The anticoagulant aPC
significantly reduced mortality in LT-treated rats. Specific
treatments to overcome LT-mediated pathogenesis are
lacking. Our findings may aid in the development of new
therapeutic strategies for treating anthrax infections.
Additional file
Additional file 1: Coagulant, lung edema and blood pressure
analyses, and a hypothetical model.
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